Astellas Net Income From Continuing Ops from 2010 to 2026
| YPH Stock | EUR 13.38 0.14 1.04% |
Net Income From Continuing Ops | First Reported 2017-03-31 | Previous Quarter 14.5 B | Current Value -33.3 B | Quarterly Volatility 31.7 B |
Check Astellas Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Astellas Pharma's main balance sheet or income statement drivers, such as Interest Expense of 21.3 B, Selling General Administrative of 600.9 B or Total Revenue of 1.5 T, as well as many indicators such as . Astellas financial statements analysis is a perfect complement when working with Astellas Pharma Valuation or Volatility modules.
Astellas | Net Income From Continuing Ops |
The Net Income From Continuing Ops trend for Astellas Pharma offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Astellas Pharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Astellas Pharma's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Astellas Pharma over the last few years. It is Astellas Pharma's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Astellas Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Astellas Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 117,313,940,294 | |
| Geometric Mean | 98,011,300,039 | |
| Coefficient Of Variation | 53.95 | |
| Mean Deviation | 51,383,820,900 | |
| Median | 98,714,000,000 | |
| Standard Deviation | 63,292,193,787 | |
| Sample Variance | 4005901794.4T | |
| Range | 205.2B | |
| R-Value | (0.36) | |
| Mean Square Error | 3726317793.1T | |
| R-Squared | 0.13 | |
| Significance | 0.16 | |
| Slope | (4,482,991,225) | |
| Total Sum of Squares | 64094428710.7T |
Astellas Net Income From Continuing Ops History
About Astellas Pharma Financial Statements
Astellas Pharma stakeholders use historical fundamental indicators, such as Astellas Pharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Astellas Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Astellas Pharma's assets and liabilities are reflected in the revenues and expenses on Astellas Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Astellas Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 45.7 B | 43.4 B |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Astellas Stock
Astellas Pharma financial ratios help investors to determine whether Astellas Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.